Notice of Results

Summary by AI ^BETAClose X

Kromek Group PLC has announced that it will release its interim results for the six months ending 31 October 2025 on Tuesday, 20 January 2026. The company will host an online question and answer session for investors on Monday, 26 January 2026, at 4:00 PM GMT, with a recording of the results presentation to be available by midday on Friday, 23 January 2026.

Disclaimer*

Kromek Group PLC

16 December 2025

Kromek Group plc

("Kromek", the "Company" or the "Group")

Notice of Results

Kromek (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, gives notice that it will be announcing its interim results for the six months ended 31 October 2025 on Tuesday 20 January 2026.

Arnab Basu, CEO, and Claire Burgess, CFO, will be hosting an online Q&A session for investors at 4.00pm GMT on Monday 26 January 2026 on the Investor Meet Company platform. A recording of the results presentation will be uploaded to the Investor Meet Company platform ahead of the webinar by midday on Friday 23 January 2026.

Questions can be submitted pre-webinar via the Investor Meet Company platform or at any time during the live webinar. Investors can sign up to Investor Meet Company for free and register to attend the Kromek Q&A session via: https://www.investormeetcompany.com/kromek-group-plc/register-investor

Enquiries

Kromek Group plc
Arnab Basu, CEO Claire Burgess, CFO	+44 (0)1740 626 060

Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance Tim Redfern - ECM Michael Johnson - Sales	+44 (0)20 7220 0500

Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury	+44 (0)20 4582 3500

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END